首页 | 本学科首页   官方微博 | 高级检索  
     

胸腺五肽治疗复治菌阳肺结核的临床效果及对患者呼吸功能的影响
引用本文:刘 岩. 胸腺五肽治疗复治菌阳肺结核的临床效果及对患者呼吸功能的影响[J]. 医学信息, 2019, 0(8): 159-160. DOI: 10.3969/j.issn.1006-1959.2019.08.049
作者姓名:刘 岩
作者单位:(佳木斯市肿瘤结核医院结核内科,黑龙江 佳木斯 154007)
摘    要:
目的 探讨胸腺五肽治疗复治菌阳肺结核的临床效果及对患者呼吸功能的影响。方法 选取2016年4月~2017年5月我院收治的74例复治菌阳肺结核患者,随机分为对照组和观察组,每组37例。对照组给予常规抗结核药物治疗,观察组加用胸腺五肽注射液治疗,比较两组治疗第1、3、6个月的痰菌阴转率、病灶吸收率、空洞闭合率,以及治疗前后用力肺活量(FVC)、第1秒用力呼气量(FEV1)、FEV1/FVC。结果 治疗后第1、3、6个月,观察组痰菌阴转率、病灶吸收率及空洞闭合率均高于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组FVC、FEV1、FEV1/FVC水平均高于对照组,差异具有统计学意义(P<0.05)。结论 胸腺五肽联合常规抗结核药物治疗复治菌阳肺结核患者,可提升复治菌阳肺结核治疗效果,改善患者呼吸功能。

关 键 词:复治菌阳肺结核  胸腺五肽  呼吸功能

Clinical Effect of Thymopentin in the Treatment of Recurrent Pulmonary Tuberculosis and its Effect on Respiratory Function
LIU Yan. Clinical Effect of Thymopentin in the Treatment of Recurrent Pulmonary Tuberculosis and its Effect on Respiratory Function[J]. Medical Information, 2019, 0(8): 159-160. DOI: 10.3969/j.issn.1006-1959.2019.08.049
Authors:LIU Yan
Affiliation:(Department of Tuberculosis,Cancer Tuberculosis Hospital,Jiamusi 154007,Heilongjiang,China)
Abstract:
Objective To investigate the clinical effect of thymopentin in the treatment of recurrent pulmonary tuberculosis and its effect on respiratory function. Methods 74 patients with retreatment of pulmonary tuberculosis admitted to our hospital from April 2016 to May 2017 were randomly divided into control group and observation group, with 37 cases in each group. The control group received conventional anti-tuberculosis drugs, and the observation group was treated with thymopentin injection. The sputum negative conversion rate, lesion absorption rate, cavity closure rate, and before and after treatment were compared between the two groups for the first, third, and sixth months of treatment. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC. Results At the first, third and sixth months after treatment, the negative conversion rate, lesion absorption rate and cavity closure rate of the observation group were higher than the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of FVC, FEV1, and FEV1/FVC in the observation group were higher than those in the control group,the difference was statistically significant (P<0.05). Conclusion Thymopentin combined with conventional anti-tuberculosis drugs for the treatment of re-treatment of pulmonary tuberculosis patients can improve the treatment effect of re-treatment of pulmonary tuberculosis and improve the respiratory function of patients.
Keywords:Re-treatment of pulmonary tuberculosis  Thymopentin  Respiratory function
点击此处可从《医学信息》浏览原始摘要信息
点击此处可从《医学信息》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号